TLR4 and Gastrointestinal dysmotility: Our findings provides the basis for a better understanding of the mechanisms underlying gastrointestinal dysmotility in presence of an anomalous neuroimmune cross talk, thereby paving the way for the development of suitable pharmacological modulators of TLR4 signaling for the management of GFD.